Printed from Voxsanity (voxsanity.com.au) — NCT07206563 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07206563
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults between 18 and 75 years of age, of any gender.
- People who have been diagnosed through a tissue or cell sample with a specific type of cancer — small-cell carcinoma of the lung or cervix — that cannot be cured by surgery or a combination of radiation and chemotherapy.
- People who have already received at least two rounds of treatment for their cancer, including treatments containing etoposide and a platinum-based drug, and whose cancer has continued to grow or spread after those treatments.
- People who have not received certain cancer treatments within specific timeframes before joining: no chemotherapy or targeted therapy within 28 days (or, for targeted therapy, 5 half-lives — whichever is shorter, but at least 14 days); no alkylating agent chemotherapy within 42 days; and no radiation therapy within 14 days (confirm with trial site if unsure which category a previous treatment falls into).
- People who have at least one area of cancer that can be clearly measured on a CT or MRI scan — specifically, a tumour measuring at least 10 mm in its longest dimension, or a lymph node measuring at least 15 mm across its shorter dimension.
- People who are generally able to carry out everyday activities with little or no limitation, as rated on a standard medical scale (ECOG score of 0 or 1).
- People who are expected to live for at least 12 weeks.
- People who have recovered from most side effects of previous cancer treatments to a mild level or better before joining, with some exceptions for certain lasting side effects that are considered safe to manage (confirm with trial site for specific situations, including nerve-related side effects from prior cisplatin or etoposide use, or lasting effects from radiotherapy).
- People whose blood test results meet specific levels for immune cells, platelets, red blood cells, kidney function, liver function, protein in the urine, and blood clotting ability (the trial site will assess these results).
- Women who test negative for pregnancy (except those who have gone through menopause or had their uterus removed); women who are sexually active and their partners must agree to use effective contraception during the trial and for 6 months after the last dose.
- People who are able to provide stored tumour tissue samples from a previous surgery or biopsy for laboratory testing — this is required only for participants joining the dose-expansion part of the trial.
- People who are able to understand the study and who give their voluntary written consent to participate, either personally or through a legal representative.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer has been identified as squamous cell carcinoma, adenocarcinoma, or another non-small-cell type of lung or cervical cancer.
- People who are currently enrolled in another clinical trial that involves an active treatment or intervention (participation in observation-only studies or follow-up phases of a completed trial may be acceptable — confirm with trial site).
- People who have a known allergy or sensitivity to penfluridol or to similar compounds.
- People who have previously received the study drug, penfluridol.
- People who have cancer that has spread to the membranes surrounding the brain or spinal cord, or who have active brain metastases causing symptoms — though people with brain metastases that have no symptoms and have been stable on scans for at least 4 weeks, and who have not needed steroids or anti-seizure medication for at least 2 weeks, may be considered (confirm with trial site).
- People who have ongoing or uncontrolled other medical conditions, including active infections, or mental health or social circumstances that would make it difficult to follow the trial requirements.
- People who are HIV-positive and are on combination antiretroviral therapy.
- People with a known history of certain heart rhythm problems (such as atrial fibrillation, an abnormally fast heart rate, or an abnormally slow heart rate — though some minor rhythm variations may be acceptable), or people who have had heart failure, a heart attack, or a stroke within the past 3 months.
- People who have had a seizure within the past 3 months.
- People who have a digestive condition that could significantly affect how the body absorbs the study drug — for example, uncontrolled nausea, vomiting, diarrhoea, a condition affecting nutrient absorption, or prior removal of part of the small intestine.
- People who have previously had an organ transplant or a bone marrow/stem cell transplant from a donor.
- People with serious, uncontrolled medical conditions — such as severe liver or kidney problems, severe heart or blood vessel disease, uncontrolled diabetes, or uncontrolled infections — that, in the treating doctor's opinion, would affect the ability to receive the study treatment.
- Women who are pregnant or breastfeeding, or sexually active women who are unwilling to use contraception.
- People who have a build-up of fluid around the lungs, abdomen, or heart that is causing symptoms or is unstable and requires repeated draining.
- People considered unsuitable for the trial by the treating doctor, for any reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
1 October 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Recommended Phase II Dose (RP2D) of penfluridol [Phase Ib]; Objective Response Rate (ORR) [Phase II]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.